[Structural development study of a novel pharmacological chaperone for folding-defective rhodopsin mutants responsible for retinitis pigmentosa].

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan

• Publication date

  2011-07-12

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/CHIN.201128277PMID 21372525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• フォールディング・トラフィッキング異常の修正作用を有するリガンドの創製 ～網膜色素変性症への応用を目指した変異型ロドプシンのフォールディングを促進するロドプシンリガンドの創製研究～

  2011cited by this paper
• Retinobenzaldehydes as proper-trafficking inducers of folding-defective P23H rhodopsin mutant responsible for retinitis pigmentosa.

  2010cited by this paper
• Molecular mechanisms of rhodopsin retinitis pigmentosa and the efficacy of pharmacological rescue.

  2010cited by this paper
• Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology.

  2010cited by this paper
• Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics

  2009cited by this paper
• Mechanism of ligand-induced folding of a natively unfolded helixless variant of rabbit I-BABP.

  2009cited by this paper
• Rational design and synthesis of highly potent pharmacological chaperones for treatment of N370S mutant Gaucher disease.

  2009cited by this paper
• Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa.

  2008cited by this paper
• Microscale fluorescent thermal stability assay for membrane proteins.

  2008cited by this paper
• Niemann-Pick Type C1 I1061T Mutant Encodes a Functional Protein That Is Selected for Endoplasmic Reticulum-associated Degradation Due to Protein Misfolding*

  2008cited by this paper
• Correctors promote folding of the CFTR in the endoplasmic reticulum.

  2008cited by this paper
• A high-throughput screening method for small-molecule pharmacologic chaperones of misfolded rhodopsin.

  2008cited by this paper
• Opioid Receptor Pharmacological Chaperones Act by Binding and Stabilizing Newly Synthesized Receptors in the Endoplasmic Reticulum*

  2007cited by this paper
• Opsin stability and folding: the role of Cys185 and abnormal disulfide bond formation in the intradiscal domain.

  2007cited by this paper
• Chemical and pharmacological chaperones as new therapeutic agents

  2007cited by this paper
• Retinitis pigmentosa.

  2006cited by this paper
• Ligands Regulate Cell Surface Level of the Human κ Opioid Receptor by Activation-Induced Down-Regulation and Pharmacological Chaperone-Mediated Enhancement: Differential Effects of Nonpeptide and Peptide Agonists

  2006cited by this paper
• Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs.

  2006cited by this paper
• The Role of the 11‐cis‐Retinal Ring Methyl Substituents in Visual Pigment Formation

  2006cited by this paper
• Rapid and simple protein-stability screens: application to membrane proteins.

  2006cited by this paper
• Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

  2005cited by this paper
• Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy.

  2005cited by this paper
• Disease-related misassembly of membrane proteins.

  2004cited by this paper
• Mutant G-protein-coupled receptors as a cause of human diseases.

  2004cited by this paper
• Retinoids Assist the Cellular Folding of the Autosomal Dominant Retinitis Pigmentosa Opsin Mutant P23H*

  2004cited by this paper
• A trip to the ER: coping with stress.

  2004cited by this paper
• The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure.

  2004cited by this paper
• Ligand specific up-regulation of a Renilla reniformis luciferase-tagged, structurally unstable muscarinic M3 chimeric G protein-coupled receptor.

  2003cited by this paper
• Pharmacological Chaperone-mediated in Vivo Folding and Stabilization of the P23H-opsin Mutant Associated with Autosomal Dominant Retinitis Pigmentosa*

  2003cited by this paper
• A Rhodopsin Mutant Linked to Autosomal Dominant Retinitis Pigmentosa Is Prone to Aggregate and Interacts with the Ubiquitin Proteasome System*

  2002cited by this paper
• Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation

  2002cited by this paper
• Rhodopsin and retinitis pigmentosa: shedding light on structure and function.

  2002cited by this paper
• Ligand Rescue of Constitutively Active Mutant Receptors

  2002cited by this paper
• Traffic Jams II: An Update of Diseases of Intracellular Transport

  2002cited by this paper
• The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation.

  2002cited by this paper
• Structure and function in rhodopsin: Mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants

  2001cited by this paper
• Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase‐tagged, constitutively active mutant, G‐protein‐coupled receptor

  2001cited by this paper
• Pharmacological chaperones: a new twist on receptor folding.

  2000cited by this paper
• Export from the Endoplasmic Reticulum Represents the Limiting Step in the Maturation and Cell Surface Expression of the Human δ Opioid Receptor*

  2000cited by this paper
• Helical membrane protein folding, stability, and evolution.

  2000cited by this paper
• Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

  2000cited by this paper
• Traffic Jam: A Compendium of Human Diseases that Affect Intracellular Transport Processes

  2000cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta(2)-adrenoceptor-green fluorescent protein fusion proteins.

  1999cited by this paper
• Probing for the Threshold Energy for Visual Transduction: Red‐Shifted Visual Pigment Analogs from 3‐Methoxy‐3‐Dehydroretinal and Related Compounds

  1999cited by this paper
• Morphological, physiological, and biochemical changes in rhodopsin knockout mice.

  1999cited by this paper
• Effect of vitamin A supplementation on rhodopsin mutants threonine-17 --> methionine and proline-347 --> serine in transgenic mice and in cell cultures.

  1998cited by this paper
• Superfolding of the Partially Unfolded Core-glycosylated Intermediate of Human P-glycoprotein into the Mature Enzyme Is Promoted by Substrate-induced Transmembrane Domain Interactions*

  1998cited by this paper
• Correction of Defective Protein Kinesis of Human P-glycoprotein Mutants by Substrates and Modulators*

  1997cited by this paper
• Retinopathy induced in mice by targeted disruption of the rhodopsin gene

  1997cited by this paper
• Structural Instability of a Constitutively Active G Protein-coupled Receptor

  1997cited by this paper
• Glycerol Reverses the Misfolding Phenotype of the Most Common Cystic Fibrosis Mutation (*)

  1996cited by this paper
• Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells.

  1996cited by this paper
• Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein.

  1996cited by this paper
• Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α

  1995cited by this paper
• Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

  1995cited by this paper
• Structure and function in rhodopsin. 7. Point mutations associated with autosomal dominant retinitis pigmentosa.

  1994cited by this paper
• Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins.

  1994cited by this paper
• Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease.

  1993cited by this paper
• Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain.

  1993cited by this paper
• Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

  1992cited by this paper
• Modulation of firefly luciferase stability and impact on studies of gene regulation.

  1991cited by this paper
• Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa.

  1991cited by this paper
• Retinobenzoic acids and nuclear retinoic acid receptors.

  1991cited by this paper
• Retinobenzoic acids. 5. Retinoidal activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60.

  1990cited by this paper
• A point mutation of the rhodopsin gene in one form of retinitis pigmentosa

  1990cited by this paper
• Retinobenzoic acids. 2. Structure-activity relationships of chalcone-4-carboxylic acids and flavone-4'-carboxylic acids.

  1989cited by this paper
• Retinobenzoic acids. 1. Structure-activity relationships of aromatic amides with retinoidal activity.

  1988cited by this paper
• Binding of a specific ligand inhibits import of a purified precursor protein into mitochondria

  1986cited by this paper
• Retinal photoreceptor-pigment epithelium interactions. Friedenwald lecture.

  1985cited by this paper
• Hemoglobin stability: observations on the denaturation of normal and abnormal hemoglobins by oxidant dyes, heat, and alkali.

  1970cited by this paper

• [Development of Biological Response Modifiers Based on Unique Medicinal Chemical Strategy].

  2021cites this paper
• Protein Misfolding Diseases and Therapeutic Approaches.

  2019cites this paper
• Emerging novel concept of chaperone therapies for protein misfolding diseases

  2014cites this paper
• Pharmacological chaperones for enzyme enhancement therapy in genetic diseases.

  2013cites this paper